Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: An approach to reduce dose and dosing frequency

International Journal of Pharmaceutics

Volumn 477, Issue 1-2, 2014, Pages 317-325

  Chandasana, Hardik ^a   Prasad, Yarra Durga ^a,c   Chhonker, Yashpal S ^a,b   Chaitanya, Telaprolu K ^a,c   Mishra, Nripendra N ^a   Mitra, Kalyan ^a,b   Shukla, Praveen K ^a,c   Bhatta, Rabi S ^a,b,c  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^c National Institute of Pharmaceutical Education and Research (NIPER)   (India)

Author keywords

Indices; Mycotic keratitis; Nanoparticles; Natamycin; Ocular drug delivery; Pharmacokinetic pharmacodynamic; Polycaprolactone

Indexed keywords

NANOPARTICLE; NATAMYCIN; ANTIFUNGAL AGENT; DELAYED RELEASE FORMULATION; EYE DROPS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; DRUG TOLERANCE; EXPERIMENTAL RABBIT; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NANOENCAPSULATION; NONHUMAN; SURFACE CHARGE; SUSTAINED DRUG RELEASE; TANDEM MASS SPECTROMETRY; ANIMAL; ASPERGILLUS FUMIGATUS; BIOLOGICAL MODEL; CANDIDA ALBICANS; CHEMISTRY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG RELEASE; EYE INFECTIONS, FUNGAL; MALE; METABOLISM; MICROBIAL SENSITIVITY TEST; PARTICLE SIZE; RABBIT; SURFACE PROPERTY; TISSUE DISTRIBUTION;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CORNEA; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; DRUG STABILITY; EYE INFECTIONS, FUNGAL; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NANOPARTICLES; NATAMYCIN; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; RABBITS; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84908501260     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.10.035     Document Type: Article

References (49)

1. Allan, C.R., Hadwiger, L.A., 1979. The fungicidal effect of chitosan on fungi of varying cell wall composition. Exp. Mycol. 3, 285-287.
2. Andrews, G.P., Laverty, T.P., Jones, D.S., 2009. Mucoadhesive polymeric platforms for controlled drug delivery. Eur. J. Pharm. Biopharm. 71, 505-518.
3. Artursson, P., Lindmark, T., Davis, S.S., Illum, L., 1994. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11, 1358-1361.
4. Barbault-Foucher, S., Gref, R., Russo, P., Guechot, J., Bochot, A., 2002. Design of poly-ε-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J. Control. Release 83, 365-375.
5. Bhatta, R., Chandasana, H., Chhonker, Y., Rathi, C., Kumar, D., Mitra, K., Shukla, P., 2012. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies. Int. J. Pharm. 432, 105-112.
6. Bhatta, R.S., Chandasana, H., Rathi, C., Kumar, D., Chhonker, Y.S., Jain, G.K., 2011. Bioanalytical method development and validation of natamycin in rabbit tears and its application to ocular pharmacokinetic studies. J. Pharm. Biomed. Anal. 54, 1096-1100.
7. Bilensoy, E., Sarisozen, C., Esendaʇli, G., Doʇan, A.L., Aktaş, Y., Şen, M., Mungan, N.A., 2009. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of mitomycin C to bladder tumors. Int. J. Pharm. 371, 170-176.
8. Bispo, V.M., Mansur, A.A., Barbosa-Stancioli, E.F., Mansur, H.S., 2010. Biocompatibility of nanostructured chitosan/poly (vinyl alcohol) blends chemically crosslinked with genipin for biomedical applications. J. Biomed. Nanotechnol. 6, 166-175.
9. Bravo-Osuna, I., Vauthier, C., Farabollini, A., Palmieri, G.F., Ponchel, G., 2007. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly (isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 28, 2233-2243.
10. Chang, H.-Y.P., Chodosh, J., 2011. Diagnostic and therapeutic considerations in fungal keratitis. Int. Ophthalmol. Clinics 51, 33-42.
11. Chowdhary, A., Singh, K., 2005. Spectrum of fungal keratitis in North India. Cornea 24, 8-15.
12. CLSI, 2006. Clinical Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7, USA.
13. Costa, P., Sousa Lobo, J.M., 2001. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13, 123-133.
14. de la Fuente, M., Ravina, M., Paolicelli, P., Sanchez, A., Seijo, B., Alonso, M.J., 2010. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv. Drug Deliv. Rev. 62, 100-117.
15. Enriquez de Salamanca, A., Diebold, Y., Calonge, M., Garcia-Vazquez, C., Callejo, S., Vila, A., Alonso, M.J., 2006. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest. Ophthalmol. Visual Sci. 47, 1416-1425.
16. Felt, O., Furrer, P., Mayer, J.M., Plazonnet, B., Buri, P., Gurny, R., 1999. Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int. J. Pharm. 180, 185-193.
17. Gopinathan, U., Garg, P., Fernandes, M., Sharma, S., Athmanathan, S., Rao, G.N., 2002. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea 21, 555-559.
18. Gratieri, T., Gelfuso, G.M., Lopez, R.F., Souto, E.B., 2010. Current efforts and the potential of nanomedicine in treating fungal keratitis. Expert Rev. Ophthalmol. 5, 365-384.
19. Greenwood, R., Kendall, K., 1999. Selection of suitable dispersants for aqueous suspensions of zirconia and titania powders using acoustophoresis. J. Eur. Ceram. Soc. 19, 479-488.
20. Huhtala, A., Salminen, L., Tähti, H., & Uusitalo, H., 2008. Corneal Models for the Toxicity Testing of Drugs and Drug Releasing Materials, in: N Ashammakhi (Ed.), Topics in multifunctional biomaterials and devices, Biomaterials and Tissue Engineering Group, Finland, pp. 1-24.
21. Iyer, S.A., Tuli, S.S., Wagoner, R.C., 2006. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens 32, 267-271.
22. Johns, K.J., O'Day, D.M., 1988. Pharmacologic management of keratomycoses. Surv. Ophthalmol. 33, 178-188.
23. Kambhampati, S.P., Kannan, R.M., 2013. Dendrimer nanoparticles for ocular drug delivery. J. Ocul. Pharm. Ther. 29, 151-165.
24. Lewis, R.E., 2007. Pharmacodynamic implications for use of antifungal agents. Curr. Opin. Pharm. 7, 491-497.
25. Lin, H.R., Yu, S.P., Lin, Y.J., Wang, T.S., 2010. High pH tolerance of a chitosan-PAA nanosuspension for ophthalmic delivery of pilocarpine. J. Biomater. Sci. Polym. Ed. 21, 141-157.
26. Liu, L., Wu, H., Riduan, S.N., Ying, J.Y., Zhang, Y., 2013. Short imidazolium chains effectively clear fungal biofilm in keratitis treatment. Biomaterials 34,1018-1023.
27. Liu, P., Müller, M., Derendorf, H., 2002. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int. J. Antimicrob. Agents 19, 285-290.
28. Losa, C., Marchal-Heussler, L., Orallo, F., Jato, J.L.V., Alonso, M.J., 1993. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm. Res. 10, 80-87.
29. Ludwig, A., 2005. The use of mucoadhesive polymers in ocular drug delivery. Adv. Drug Deliv. Rev. 57, 1595-1639.
30. Marchal-Heussler, L., Fessi, H., Devissaguet, J.P., Hoffman, M., Maincent, P., 1992. Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: polyisobutylcyanoacrylate polylactic-co-glycolic, acidpoly-epsilon-caprolacton. STP Pharma. Sci. 2, 98-104.
31. Marchal-Heussler, L., Sirbat, D., Hoffman, M., Maincent, P., 1993. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm. Res. 10, 386-390.
32. Nagarwal, R.C., Singh, P., Kant, S., Maiti, P., Pandit, J., 2010. Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye. J. Biomed. Nanotechnol. 6, 648-657.
33. Paolicelli, P., de la Fuente, M., Sánchez, A., Seijo, B., Alonso, M.J., 2009. Chitosan nanoparticles for drug delivery to the eye. Expert Opin. Drug Deliv. 6, 239-253.
34. Patel, A., Hammersmith, K., 2008. Contact lens-related microbial keratitis: recent outbreaks. Curr. Opin. Ophthalmol. 19, 302-306.
35. Phan, C.-M., Subbaraman, L., Liu, S., Gu, F., Jones, L., 2014. In vitro uptake and release of natamycin Dex-b-PLA nanoparticles from model contact lens materials. J. Biomater. Sci. Polym. Ed. 25, 18-31.
36. Qaqish, R., Amiji, M., 1999. Synthesis of a fluorescent chitosan derivative and its application for the study of chitosan-mucin interactions. Carbohydr. Polym. 38, 99-107.
37. Rosa Jr., R., Miller, Alfonso, D., 1994. The changing spectrum of fungal keratitis in south Florida. Ophthalmology 101, 1005.
38. Schentag, J.J., Gilliland, K.K., Paladino, J.A., 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32, S39-S46.
39. Schipper, N.G., Olsson, S., Hoogstraate, J.A., deBoer, A.G., Varum, K.M., Artursson, P., 1997. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res. 14, 923-929.
40. Shokohi, T., Nowroozpoor-Dailami, K., Moaddel-Haghighi, T., 2006. Fungal keratitis in patients with corneal ulcer in Sari, Northern Iran. Arch. Iran. Med. 9, 222-227.
41. Siepmann, J., Siepmann, F., 2013. Mathematical modeling of drug dissolution. Int. J. Pharm. 453, 12-24.
42. Tanure, M.A., Cohen, E.J., Sudesh, S., Rapuano, C.J., Laibson, P.R., 2000. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea 19, 307-312.
43. Thomas, P.A., 2003. Current perspectives on ophthalmic mycoses. Clin. Microbiol. Rev. 16, 730-797.
44. USFDA, 2008. NDA 50-514/S-009 Page 3 NATACYN® (natamycin ophthalmic suspension) http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/050514s009lbl.pdf (accessed 31.05.14).
45. van der Merwe, S.M., Verhoef, J.C., Verheijden, J.H., Kotze, A.F., Junginger, H.E., 2004. Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur. J. Pharm. Biopharma.: Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 58, 225-235.
46. Wilhelmus, K.R., 2001. The Draize eye test. Surv. Ophthalmol. 45, 493-515.
47. Xie, L., Dong, X., Shi, W., 2001. Treatment of fungal keratitis by penetrating keratoplasty. Br. J. Ophthalmol. 85, 1070-1074.
48. Xie, L., Zhong, W., Shi, W., Sun, S., 2006. Spectrum of fungal keratitis in north China. Ophthalmology 113, 1943-1948.
49. Yildiz, E.H., Abdalla, Y.F., Elsahn, A.F., Rapuano, C.J., Hammersmith, K.M., Laibson, P. R., Cohen, E.J., 2010. Update on fungal keratitis from 1999 to 2008. Cornea 29, 1406-1411.